Quick Answer
A landmark Lancet trial published July 2026 shows Eli Lilly orforglipron pill outperforms oral semaglutide — more weight loss, better blood sugar, no refrigeration or meal timing rules. Indian regulatory approval could follow within 12-18 months.
Get Free Expert Consultation
Speak to a GLP-1 Therapy specialist — callback in 30 minutes
A landmark head-to-head clinical trial published in The Lancet on July 7, 2026 has confirmed that the Eli Lilly oral GLP-1 pill orforglipron outperforms oral semaglutide on both weight loss and blood sugar control in people with type 2 diabetes. For millions of Indian patients who have been reluctant to start GLP-1 therapy because of the weekly injection format, these results could mark a turning point: a pill that works better than the existing oral option, requires no refrigeration, and can be taken at any time with any food.
What the Lancet Trial Found
The trial pitted orforglipron directly against oral semaglutide — the pill form of Ozempic, sold as Rybelsus in India — in a head-to-head comparison in adults with type 2 diabetes. Participants taking orforglipron lost an average of 6.1 to 8.2 kilograms over the course of the study, compared to 5.3 kilograms for those on oral semaglutide. Orforglipron also produced meaningfully greater reductions in HbA1c — the standard long-term blood sugar marker — and outperformed oral semaglutide across multiple metabolic measures including blood pressure and cholesterol. The results were reported in The Lancet, one of the most respected medical journals in the world, giving them strong clinical weight.
Why Orforglipron Is Easier to Use Than Oral Semaglutide
Both orforglipron and oral semaglutide are pills — but the practical experience of taking them is very different.
Oral semaglutide comes with a strict set of requirements: it must be taken on an empty stomach, with no more than 120 ml of plain water, and you must wait at least 30 minutes before eating or drinking anything else. If you eat before that window closes, the drug is not properly absorbed and its effectiveness drops significantly. For many Indian patients — especially those with an early-morning chai habit, young children to feed, or simply busy mornings — this restriction is genuinely difficult to follow reliably.
Get Free Expert Consultation
Speak to a GLP-1 Therapy specialist — callback in 30 minutes
Orforglipron has none of these restrictions. It can be taken at any time of day, with or without food, and with any quantity of fluid. It does not require refrigeration, which also sets it apart from injectable GLP-1 pens that must be kept cold until first use. For patients in India who travel frequently, live in areas with unreliable power supply, or simply want a flexible daily routine, this is a meaningful practical advantage.
There is also a manufacturing difference that matters for long-term affordability. Orforglipron is a small-molecule drug — a chemically simpler type of compound — while semaglutide is a peptide that is more complex and expensive to manufacture at scale. Small molecules are typically cheaper to produce, which could translate into lower prices once orforglipron reaches the broader market.
Why This Matters for Indian Patients
India has approximately 77 million people living with type 2 diabetes, making it the second-largest diabetic population in the world. Despite this, a large proportion of diabetic patients in India remain on older oral medications like metformin or sulfonylureas alone — drugs that control blood sugar but do not produce the weight loss, cardiovascular protection, or kidney benefits that GLP-1 drugs have consistently demonstrated in major clinical trials.
The primary reason many Indian patients have not started GLP-1 therapy is not cost alone — it is the injection. Weekly self-injection remains a barrier for a significant proportion of patients, particularly those who are older, needle-averse, or managing their condition without close specialist support. An oral GLP-1 pill that outperforms the existing tablet option and is far simpler to use could substantially change this picture.
The Lancet trial results also matter for Indian patients already on oral semaglutide. If orforglipron is approved and launched in India, those patients may have an option that is both more effective and easier to take consistently.
Get Free Expert Consultation
Speak to a GLP-1 Therapy specialist — callback in 30 minutes
When Will Orforglipron Be Available in India?
Orforglipron has not yet received approval from the Central Drugs Standard Control Organisation, the Indian drug regulator. However, Eli Lilly submitted the drug to the US Food and Drug Administration for approval in early 2026. If the FDA approves it — which analysts widely expect given the strong Phase 3 results — Indian regulatory review could follow within 12 to 18 months under standard timelines. Given the scale of India's diabetic population and the strength of the clinical evidence, an expedited review pathway is also possible.
What to Do Now
If you have type 2 diabetes and are not yet on a GLP-1 medication, you do not need to wait for orforglipron. Injectable semaglutide and tirzepatide are already approved and available in India, and generic semaglutide from manufacturers including Natco Pharma and Cipla is now available from as low as Rs 1,290 per month — a significant reduction from branded pricing. A GLP-1 specialist can assess whether you are a good candidate, recommend the right medication for your situation, and monitor your progress. If you are specifically interested in an oral option, oral semaglutide (Rybelsus) is available now while orforglipron moves through the regulatory process.
Call MySurgery at 8588967050 or WhatsApp us to speak with a GLP-1 specialist. Free consultation, callback in 30 minutes.
Disclaimer: This article is based on information published on the referenced websites below and is intended for general awareness only. It is not a substitute for professional medical advice.
References: 1. ScienceDaily — https://www.sciencedaily.com/releases/2026/07/260707054111.htm 2. Scientific American — https://www.scientificamerican.com/article/head-to-head-trial-shows-eli-lillys-oral-glp-1-orforglipron-outperforms-oral/ 3. Eli Lilly and Company — https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-statistically
MySurgery GLP-1 Team
GLP-1 Research & Patient Education
Have questions about GLP-1 Therapy?
Free consultation. Expert doctors. Callback in 30 minutes.